fig1

Figure 1. Tumor characteristics. (A) Clinical trial patient tumor types and grades. (B) Representative intra-nuclear Ki67 and FVIII-related antigen expression in canine glioma tumor microenvironment. (C) Percentages of Ki67 expression in controls (n = 3), astrocytomas {n = 9 [4 patient astrocytomas and 5 astrocytomas from dogs not in the clinical trial (A1-5)]}; and oligodendrogliomas (n = 10). (D) Numbers of FVIII-related antigen positive endothelial cells/10 cumulative high power fields in the same tumors. One-way analysis of variance (column analyses) with Sidak’s correction for multiple comparisons was applied with *P < 0.05 indicative of statistical significance for oligodendroglioma vs. control samples.